JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 1, 2006; DOI: 10.1124/jpet.106.109504


0022-3565/06/3193-1124-1132$20.00
JPET 319:1124-1132, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.109504v1
319/3/1124    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhao, L.
Right arrow Articles by Brinton, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhao, L.
Right arrow Articles by Brinton, R. D.

NEUROPHARMACOLOGY

Estrogenic Agonist Activity of ICI 182,780 (Faslodex) in Hippocampal Neurons: Implications for Basic Science Understanding of Estrogen Signaling and Development of Estrogen Modulators with a Dual Therapeutic Profile

Liqin Zhao, Kathleen O'Neill, and Roberta Diaz Brinton

Department of Molecular Pharmacology and Toxicology, Norris Foundation Laboratory for Neuroscience Research, School of Pharmacy, University of Southern California, Los Angeles, California

The present study sought to determine the characteristics of ICI 182,780 (Faslodex) action in rat primary hippocampal neurons. We first investigated the neuroprotective efficacy of ICI 182,780 against neurodegenerative insults associated with Alzheimer's disease and related disorders. Dose-response analyses revealed that ICI 182,780, in a concentration-dependent manner, significantly promoted neuron survival following exposure to either excitotoxic glutamate (200 µM)- or beta-amyloid1–42 (1.5 µM)-induced neurodegeneration of hippocampal neurons. At a clinically relevant concentration of 50 ng/ml, ICI 182,780 exerted nearly maximal neuroprotection against both insults with efficacy comparable with that induced by the endogenous estrogen 17beta-estradiol. Thereafter, we investigated the impact of 50 ng/ml ICI 182,780 on mechanisms of 17beta-estradiol-inducible neuronal plasticity and neuroprotection. Results of these analyses demonstrated that ICI 182,780 directly induced a series of rapid intracellular Ca2+ concentration ([Ca2+]i) oscillations in a pattern comparable with that of 17beta-estradiol. In addition, ICI 182,780 exerted dual regulation of the glutamate-induced rise in [Ca2+]i identical to that induced by 17beta-estradiol. Further analyses demonstrated that ICI 182,780 induced significant activation of extracellular signal-regulated kinase 1/2 and Akt (protein kinase B) and significantly increased expression of spinophilin and Bcl-2, with efficacy comparable with neurons treated with 17beta-estradiol. Taken together, results of these in vitro analyses of ICI 182,780 provide direct evidence of an estrogenic agonist profile of ICI 182,780 action in rat hippocampal neurons. Therapeutic development of neuroselective estrogen receptor modulators that mimic ICI 182,780 is discussed with respect to the potential of safe and efficacious alternatives to estrogen therapy for the prevention of postmenopausal cognitive decline and late-onset Alzheimer's disease.


Received for publication June 21, 2006
Accepted August 31, 2006.

Address correspondence to: Dr. Roberta Diaz Brinton, Molecular Pharmacology and Toxicology, Neuroscience, and Biomedical Engineering, University of Southern California, 1985 Zonal Avenue, PSC 503, Los Angeles, CA 90089. E-mail: rbrinton{at}usc.edu




This article has been cited by other articles:


Home page
EndocrinologyHome page
L. Zhao, Z. Mao, and R. D. Brinton
A Select Combination of Clinically Relevant Phytoestrogens Enhances Estrogen Receptor {beta}-Binding Selectivity and Neuroprotective Activities in Vitro and in Vivo
Endocrinology, February 1, 2009; 150(2): 770 - 783.
[Abstract] [Full Text] [PDF]


Home page
Therapeutic Advances in Neurological DisordersHome page
J. W. Simpkins, E. Perez, Xiaofei Wang, ShaoHua Yang, Yi Wen, and M. Singh
The Potential for Estrogens in Preventing Alzheimer's Disease.
Therapeutic Advances in Neurological Disorders, January 1, 2009; 2(1): 31 - 49.
[Abstract] [PDF]


Home page
J Mol EndocrinolHome page
A. M Davis, J. Mao, B. Naz, J. A Kohl, and C. S Rosenfeld
Comparative effects of estradiol, methyl-piperidino-pyrazole, raloxifene, and ICI 182 780 on gene expression in the murine uterus
J. Mol. Endocrinol., October 1, 2008; 41(4): 205 - 217.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
P. D. Alfinito, X. Chen, J. Atherton, S. Cosmi, and D. C. Deecher
ICI 182,780 Penetrates Brain and Hypothalamic Tissue and Has Functional Effects in the Brain after Systemic Dosing
Endocrinology, October 1, 2008; 149(10): 5219 - 5226.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.